Cedar Mountain Advisors
AZN icon

Cedar Mountain Advisors’s AstraZeneca AZN Stock Holding History

Cedar Mountain Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.1K Sell
13
-6
-32% -$1K ﹤0.01% 808
2026
Q2 		$3.6K Sell
19
-6
-24% -$1.13K ﹤0.01% 773
2026
Q1 		$4.93K Buy
25
+2
+9% +$386 ﹤0.01% 661
2025
Q4 		$4.14K Buy
23
+16
+229% +$2.81K ﹤0.01% 334
2025
Q3 		$997 Buy
+7
New +$1.06K ﹤0.01% 531

Other funds holding AZN

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Aviva
Aviva London, United Kingdom $70.5B AUM 31.52% 1-Year Est. Return
Mitsubishi UFJ Trust & Banking
Mitsubishi UFJ Trust & Banking Tokyo, Japan $47.2B AUM 26.24% 1-Year Est. Return

Cedar Mountain Advisors's AZN Position: Q3 2026 in Review

Cedar Mountain Advisors reduced its AstraZeneca (AZN) stake by 32% in Q3 2026, selling an estimated $1K and leaving 13 shares worth $2.1K. The position accounts for ﹤0.01% of the portfolio, ranked #808.

Cedar Mountain Advisors first reported a position in AZN in Q3 2025 and has held it in 5 quarters since. The position peaked at $4.93K in Q1 2026. 1,039 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Cedar Mountain Advisors held 13 shares of AstraZeneca worth $2.1K as of Q3 2026.
  • Cedar Mountain Advisors sold 6 AstraZeneca shares in Q3 2026, an estimated $1K.
  • AstraZeneca made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q3 2026, its #808 holding.
  • Cedar Mountain Advisors first reported a position in AstraZeneca in Q3 2025 and has held it in 5 quarters since.
  • Cedar Mountain Advisors's AstraZeneca position peaked at $4.93K in Q1 2026.
  • 1,039 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Cedar Mountain Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.